Ex-OpenAI Scientist Secures $215 Million to Deploy Robots in Wet‑Lab Research

A new biotech startup, Warp Science, announced its formation this week, unveiling a $215 million financing round led by venture firm Lightspeed. The capital will be used to develop robotic systems that can perform routine laboratory procedures, from pipetting to sample handling, with the aim of turning traditional wet‑lab work into a largely automated process.

The company’s founder previously headed the science team at OpenAI, where he oversaw research that blended artificial intelligence with experimental methods. After leaving the AI firm, he turned his attention to the bottlenecks that still plague biological research, noting that many experiments remain labor‑intensive despite advances in computational tools.

Warp Science plans to integrate modular robotic arms, vision‑based quality control, and software that can translate experimental protocols into machine‑readable instructions. By handling repetitive tasks, the platform is intended to free scientists for higher‑order analysis and accelerate the pace of discovery, particularly in drug development and synthetic biology where throughput and reproducibility are critical.

The infusion of $215 million places Warp Science among a growing cohort of companies seeking to modernize laboratory infrastructure. Venture capital has increasingly flowed into automation, with firms such as Benchling, LabTwin, and others attracting sizable investments in recent years. Industry observers view the sizable round as a vote of confidence in the commercial viability of fully robotic wet‑lab workflows, a segment that has historically lagged behind data‑centric AI applications.

While the technology is still in prototype stages, Warp Science aims to launch its first commercial system within the next 12 to 18 months, targeting large research institutions and pharmaceutical R&D labs. The company will need to navigate regulatory considerations surrounding laboratory equipment and demonstrate consistent reliability before broader adoption. If successful, the venture could reshape how experimental biology is conducted, ushering in an era where robots handle the routine, and scientists focus on hypothesis generation and interpretation.